EMA Endorses Use Of Dexamethasone In COVID-19
The Move Should Speed Up EU National Approvals
Executive Summary
Companies marketing dexamethasone in Europe have been told they can use a CHMP endorsement to request the addition of COVID-19 to their product license.
You may also be interested in...
EMA Reviewing Two MAb Combinations For COVID-19
The European Medicines Agency's special review process that was used to help EU member states issue emergency use approvals for dexamethasone in COVID-19 patients is now being applied to two antibody combinations from Regeneron/Roche and Lilly.
COVID-19: EU Dexamethasone Taw Filing Pulled
The withdrawal of the marketing authorization application for Dexamethasone Taw as a treatment for COVID-19 patients was revealed today in the January meeting agenda of the European Medicines Agency’s human medicines committee, the CHMP.
‘Unprecedented’ EMA Response To COVID-19 Must Be Sustained
The agility, flexibility and transparency that the European Medicines Agency has adopted during the development and assessment of COVID-19 products will have to continue after treatments and vaccines are on the market, says the soon-to-be new head of the agency, Emer Cooke.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: